Clinical efficacy of intensity modulated radiotherapy with oral S-1 for locally advanced pancreatic cancer
10.3760/cma.j.issn.1673-4904.2015.08.012
- VernacularTitle:调强放疗联合口服替吉奥化疗治疗局部进展期胰腺癌的疗效观察
- Author:
Meiyue TANG
;
Yu SHI
;
Siliang WANG
;
Rong WU
- Publication Type:Journal Article
- Keywords:
Radiotherapy,intensity-modulated;
Pancreatic neoplasms;
S-1
- From:
Chinese Journal of Postgraduates of Medicine
2015;38(8):587-590
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the feasibility and efficacy of the intensity modulated radiotherapy (IMRT) with oral S-1 for locally advanced pancreatic cancer.Methods Forty-two patients with locally advanced pancreatic cancer were selected,and the patients were divided into 2 groups by random digits table method with 21 cases each.The patients in treatment group were treated by IMRT combined with oral S-1 40 mg/m2 twice daily from day 1 to day 14 of a 21-d cycle;the patients in control group were treated by IMRT combined with 30 min intravenous infusions of gemcitabine 1 000 mg/m2 on day 1,8,21 and 29.Radiation was concurrently delivered at a dose of 50.4 Gy (1.8 Gy/d,5 times per week,28 fractions).The dose of intensity modulated radiotherapy was 1.8 Gy/time (5 times/week,50.4 Gy/28 times).The recent curative effect and untoward reaction were assessed at the end of radiotherapy after 4 weeks.Results There were no statistical differences in efficient rate and disease control rate between treatment group and control group:57.1% (12/21) vs.47.6% (10/21) and 85.7% (18/21) vs.76.2% (16/21),P > 0.05.The neutropenia rate and thrombocytopenia rate in treatment were significantly lower than those in control group:23.8% (5/21) vs.57.1% (12/21) and 28.6% (6/21) vs.66.7% (14/21),and there were statistical differences (P < 0.05).There were no statistical differences in the incidences of anemia,nausea,vomiting,elevated aminotransferase and fatigue (P> 0.05).Conclusions The IMRT with oral S-1 for locally advanced pancreatic cancer is safe and effective.It is worthy of clinical promotion.